National Jewish Health has more experience diagnosing and treating beryllium sensitization (BeS) and chronic beryllium disease (CBD) than any other hospital in the world. We emphasize early disease detection, regular follow-up and consultation with local health care providers, and treatment when needed to stop or slow disease progression. We offer diagnosis and treatment for individuals who are exposed to beryllium and consultative services to industries to assist with developing medical surveillance programs to identify workers with beryllium sensitization.
Beryllium Sensitivity Testing
Beryllium Medical Care
The National Jewish Health beryllium team treats more than 500 patients with BeS or CBD each year, and our hospital is an Occupational Safety and Health Administration (OSHA) Designated CBD Diagnostic Center.
Our comprehensive diagnostic capabilities include:
Our patients also have access to clinical trials.
Beryllium Medical Surveillance for Companies
The National Jewish Health beryllium team has more than three decades of experience working with employer health and safety teams to ensure compliance with OSHA standards, uphold worker safety standards and reduce healthcare expenses.
Learn more about Beryllium Medical Surveillance
As one of the top research centers in the country, the National Jewish Health beryllium team, working with industry partners, have described how BeS and CBD are distributed throughout workforces in North America. Our researchers have defined the genetic, exposure level, and immunologic factors that result in CBD. This ongoing research includes work on the predictors of who will develop BeS, in order to prevent and treat CBD. National Jewish Health is committed to studying beryllium-related disease from every angle using multiple innovative approaches.